PATENT CLAIM ANALYSIS

Application Number: 15775810
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-10
Patent Classification: ["514", "547000"]

Abstract:
The present invention provides methods for treating, controlling or mitigating paroxysmal nocturnal hemoglobinuria (PNH), comprising administering a monoacetyldiacylglycerol compound to a patient in need thereof, as well as compositions useful therefor.

Claim (Index 13):
The method of  claim 1  wherein the patient exhibits reduced or absent levels of CD55 and CD59 presentation on erythrocytes, e.g., wherein flow cytometry for CD55 and CD59 is used to categorize erythrocytes as type I, II, or III, wherein type I cells have normal levels of CD55 and CD59; type II have reduced levels; type III have absent levels, and a PNH patient in need of treatment is one with type II or type III erythrocytes.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 93.0
- Lexical Diversity: 1.12121
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15775811', '14936464', '14951353', '14912920', '14959750']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.764810124045913
- 35 USC 102 Novelty (BERT): 0.5602923772363781
- Combined Prediction Score: 0.7443583493649595
- Mean Citation Score: 340.9169940000001
- Max Citation Score: 453.0318
- Similarity Product: 281.9211621317625

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test